Journal article

The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis

Veronica Tsin Fong Voo, Helmut Butzkueven, Jim Stankovich, Terence O'Brien, Mastura Monif

MULTIPLE SCLEROSIS AND RELATED DISORDERS | ELSEVIER SCI LTD | Published : 2021

Abstract

Cladribine is an approved selective immune reconstitution therapy for relapsing-remitting MS (RRMS). It was first developed and used to treat various forms of cancer, particularly leukemia via parenteral administration. The oral tablet version of cladribine was later developed to treat RRMS, an autoimmune disorder of the central nervous system (CNS) with periods of relapse and remission. Cladribine is found to selectively deplete adaptive immune cell types, and its role on innate immune cells is largely unknown. Among the lymphocyte populations and subtypes, the magnitude and kinetics of depletion by cladribine vary substantially. The current consensus on the selective cytotoxic effect of cl..

View full abstract